Gilead Sciences Q2 26 Earnings
Revenue: $7.80B (est $7.40B) Adjusted Loss/Share: $6.75 (est loss/share $7.17) Trodelvy Revenue: $457M (est $423.2M) Biktarvy Revenue: $3.77B (est $3.60B) Veklury Revenue: $23M (est $98.1M) Sees FY Product Sales: $30.1B To $30.4B (est $30.06B) Sees FY Adjusted Loss/Share: 30c To 65c Sees FY Veklury Revenue: $300M, Saw